Iridex Q2 revenue down 7% to $12.6M; glaucoma G6 up 19%, retina weak

IRIDEX CORP

Total revenue $12.6M, down 7% YoY; net loss $1.3M ($0.07/share) vs $1.0M loss prior year.
Cyclo G6 family revenue $3.9M (+19% YoY) on 17,700 probes sold (+35% volume); retina revenue $6.5M vs $8.0M.
Non-GAAP adjusted EBITDA loss $0.4M vs +$21K prior year; operating cash flow positive in Q2.
Reaffirms FY2026 revenue guidance $51-53M; adjusted opex $19-19.5M; cash $4.7M.
Retina decline due to Middle East disruptions and China sell-through; expects improvement with Pascal platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.